Cargando…
A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond
A small but significant proportion of COVID‐19 patients develop life‐threatening cytokine storm. We have developed a new anti‐inflammatory drug, EXO‐CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF‐kB pathway and the production of cytokines/...
Autores principales: | Shapira, Shiran, Ben Shimon, Marina, Hay‐Levi, Mori, Shenberg, Gil, Choshen, Guy, Bannon, Lian, Tepper, Michael, Kazanov, Dina, Seni, Jonathan, Lev‐Ari, Shahar, Peer, Michael, Boubas, Dimitrios, Stebbing, Justin, Tsiodras, Sotirios, Arber, Nadir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349550/ https://www.ncbi.nlm.nih.gov/pubmed/35776000 http://dx.doi.org/10.15252/emmm.202215997 |
Ejemplares similares
-
The Big Potential of Small Particles: Lipid-Based Nanoparticles and Exosomes in Vaccination
por: Shimon, Marina Ben, et al.
Publicado: (2022) -
Predictors of the CD24/CD11b Biomarker among Healthy Subjects
por: Shapira, Shiran, et al.
Publicado: (2021) -
Innovative dual system approach for selective eradication of cancer cells using viral-based delivery of natural bacterial toxin–antitoxin system
por: Shapira, Shiran, et al.
Publicado: (2021) -
Inhaled Exosomes Genetically Manipulated to Overexpress CD24 (EXO-CD24) as a Compassionate Use in Severe ARDS Patients
por: Green, Orr, et al.
Publicado: (2023) -
Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers
por: Shapira, Shiran, et al.
Publicado: (2016)